Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Ongoing; Histology Results Expected 1H24 Phase 1 Trial of Oral VK2735 Continues to Enroll; Results Expected 1Q24 Strong Quarter-End Cash Position of $376M SAN DIEGO Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2023 , and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended September 30, 2023 , and Other Recent Events: "The third quarter of 2023 has been an exciting period for Viking," stated Brian Lian , Ph.D., chief executive officer of Viking. "We filed an IND for a Phase 2 trial for our newest program, VK2735, for obesity, and subsequently initiated the Phase 2 VENTURE study to
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain [Seeking Alpha]Seeking Alpha
- Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program [Yahoo! Finance]Yahoo! Finance
- Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi-Year Run [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 11/5/25 - Form SCHEDULE
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- VKTX's page on the SEC website